Evidence map›Paper›PMID 30229462›Full record

Trial reportHigh blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension2018

Optimizing Lipid Pattern by Adding a Combined Nutraceutical or Pravastatin to Fenofibrate Treatment in Hypertriglyceridemic Subjects: Single Site, Randomized, Open-Label, Post-Market Clinical Investigation.

Arrigo F G Cicero, Federica Fogacci, Marilisa Bove, Fulvio Ventura, Marina Giovannini, Claudio Borghi

Abstract readComparative StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 6 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Arrigo F G CiceroAtherosclerosis Research Unit, Medical and Surgical Sciences Department, Sant'Orsola-Malpighi Hospital, Alma Mater Studiorum University of Bologna, Via Albertoni, 15, 40138, Bologna, Italy. arrigo.cicero@unibo.it.
Federica FogacciAtherosclerosis Research Unit, Medical and Surgical Sciences Department, Sant'Orsola-Malpighi Hospital, Alma Mater Studiorum University of Bologna, Via Albertoni, 15, 40138, Bologna, Italy.
Marilisa BoveAtherosclerosis Research Unit, Medical and Surgical Sciences Department, Sant'Orsola-Malpighi Hospital, Alma Mater Studiorum University of Bologna, Via Albertoni, 15, 40138, Bologna, Italy.
Fulvio VenturaAtherosclerosis Research Unit, Medical and Surgical Sciences Department, Sant'Orsola-Malpighi Hospital, Alma Mater Studiorum University of Bologna, Via Albertoni, 15, 40138, Bologna, Italy.
Marina GiovanniniAtherosclerosis Research Unit, Medical and Surgical Sciences Department, Sant'Orsola-Malpighi Hospital, Alma Mater Studiorum University of Bologna, Via Albertoni, 15, 40138, Bologna, Italy.
Claudio BorghiAtherosclerosis Research Unit, Medical and Surgical Sciences Department, Sant'Orsola-Malpighi Hospital, Alma Mater Studiorum University of Bologna, Via Albertoni, 15, 40138, Bologna, Italy.
Policlinico S.Orsola-Malpighi · ITUniversity of Bologna · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionFenofibrate is an effective and safe treatment for hypertriglyceridemia. However, after TG reduction a residual dyslipidemia could appear and require further treatment.

aimTo comparatively evaluate the short-term tolerability and efficacy of a combined lipid-lowering nutraceutical and pravastatin 40 mg in fenofibrate treated patients.

methodWe prospectively enrolled 40 patients well-tolerating treatment with micronized fenofibrate 145 mg/day and with residual dyslipidemia (LDL-C > 115 mg/dL and TG > 150 mg/dL). Exclusion criteria have been type 2 diabetes, Familial Hypercholesterolemia, previous cardiovascular diseases and severe chronic kidney disease. Then, we have randomly assigned the patients to treatment with pravastatin 40 mg or a combined lipid-lowering nutraceutical (Armolipid Plus

resultsAfter 8 weeks of treatment, 80% of pravastatin treated patients (N. 16/20) and 75% of those treated with Armolipid Plus

conclusionIn hypertriglyceridemic patients treated with fenofibrate, the association with a combined lipid lowering nutraceutical seem to be more effective in optimizing residual hypertriglyceridemia than pravastatin 40 mg, while being more tolerable and having similar effect on LDL-C plasma level.

Indexed as

Dietary SupplementsBiomarkersDown-RegulationDrug Therapy, CombinationFemaleFenofibrateHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypertriglyceridemiaItalyMalePravastatinProduct Surveillance, PostmarketingProspective StudiesTime FactorsTreatment OutcomeBiomarkersFenofibrateHydroxymethylglutaryl-CoA Reductase InhibitorsPravastatinTriglyceridesClinical trialFenofibrateHypertriglyceridemiaNutraceuticalsPravastatin

Identifiers

PMID30229462
OpenAlexW2890865150

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.